Skip to main content
Top
Published in: Investigational New Drugs 1/2002

01-02-2002

Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice

Authors: Lisa Polin, Kathryn White, Juiwanna Kushner, Jennifer Paluch, Chiab Simpson, Susan Pugh, Matthew K. Edelstein, Stuart Hazeldine, Joseph Fontana, Patricia LoRusso, Jerome P. Horwitz, Thomas H. Corbett

Published in: Investigational New Drugs | Issue 1/2002

Login to get access
Metadata
Title
Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice
Authors
Lisa Polin
Kathryn White
Juiwanna Kushner
Jennifer Paluch
Chiab Simpson
Susan Pugh
Matthew K. Edelstein
Stuart Hazeldine
Joseph Fontana
Patricia LoRusso
Jerome P. Horwitz
Thomas H. Corbett
Publication date
01-02-2002
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 1/2002
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1014469828729

Other articles of this Issue 1/2002

Investigational New Drugs 1/2002 Go to the issue

Instructions for Authors

Instructions for Authors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine